Power of the Dream Ventures, Genetic Immunity Announces Positive Phase II Data for DermaVir HIV therapeutic Vaccine; Results Show 70% Viral Load Reduction
BUDAPEST, HUNGARY, Apr 11, 2011 (MARKETWIRE via COMTEX) -- Power of the Dream Ventures, Inc. (OTCBB: PWRV), Hungary's premier technology acquisition and development company, is pleased to announce Genetic Immunity's Phase II trial results for the Company's Lead Product candidate called DermaVir, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on a going forward basis.
DermaVir, the world's first topical dendritic cell-targeting HIV therapeutic vaccine candidate, employs nanotechnology to boost the patient's own immune responses and to kill HIV-infected cells. The goal of DermaVir immune boosting therapy is to decrease antiretroviral drug exposure while maintaining undetectable HIV-RNA levels and achieve a remission (functional cure) in HIV-infected patients.
In a randomized, placebo-controlled, dose-ranging Phase II study conducted in Hamburg, Germany, thirty-six HIV-infected individuals, not yet taking antiretroviral drugs, received one of three DermaVir doses, or the placebo, every six weeks. "The treatments were very well-tolerated and CD4+ cell counts did not decrease," explained the study's Principle Investigator, Jan van Lunzen, MD of the University Medical Center Hamburg-Eppendorf, Infectious Diseases Unit. "At 24 weeks, the individuals' HIV viral loads were compared to their baseline values. A statistically significant reduction of 0.5 log10 copies/mL, a 70 percent reduction equivalent to that produced by several anti-HIV drugs, was seen in the cohort receiving 0.4 mg DermaVir vaccinations. Also in this group, HIV gag-specific precursor/memory T cells increased by 97 percent as the viral load decreased, a result not seen with antiretroviral drugs. Based upon our study the immune boosting and antiviral activity of DermaVir immunizations may provide a unique treatment approach for people with HIV/AIDS."
DermaVir features all key technological elements of Genetic Immunity's Immune Therapy Technology Platform. The Active Pharmaceutical Ingredient of DermaVir is a single plasmid DNA immunogen safely expressing 15 HIV antigens, the broadest antigen repertoire seen among HIV vaccine candidates to date. DermaVir Product is a "pathogen-like" nanomedicine and it is administered topically with a medical device, called DermaPrep. This technology in vivo targets the antigens to dendritic cells to prime naive T cells and expand the HIV-specific T cell pool to kill HIV-infected cells.
"Unlike traditional vaccines that prevent disease, therapeutic vaccines are given to people who are already infected to boost the body's immune response. To live a better and longer life, HIV-infected people boost their immune systems with vitamins, dietary supplements and herbs. We designed DermaVir to specifically boost their immune system to kill their HIV-infected cells and win the battle. Our Phase II trial provides the human proof of concept that immune boosting with DermaVir can reduce HIV viral load by killing the infected cells," said Julianna Lisziewicz, PhD and CEO of Genetic Immunity.
About PDV Power of the Dream Ventures, Inc. is a leading technology holding company. We identify and harness the unique technological prowess of Hungary's high-tech industry, turning promising ideas and ready to market products/technologies into global industry leaders. We focus on developing, acquiring, licensing, or co-developing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; emerging science and high-technology research projects that require help in patenting, developing the product and marketing, University spin-off technologies, and ideas from the very early stage that represent "disruptive technologies." For more information, please visit http://www.powerofthedream.com
About Genetic Immunity
Genetic Immunity is a privately held US/Hungarian biotechnology company developing a new class of immunotherapeutic biologics for the treatment of viral infections, cancer and allergy. The Company's proprietary Immune Therapy Technology Platform is based on dendritic cell-targeting topical nanomedicines. For more information please visit http://www.geneticimmunity.com
DermaVir is a novel therapeutic HIV vaccine with both antiviral and immunomodulating activities. Genetic Immunity believes that DermaVir has the potential to offer a paradigm change in the treatment of HIV/AIDS based on clinical data showing boosting of HIV-specific T cells and decrease of HIV-infected cells that are not eliminated by antiretroviral drugs. DermaVir has an excellent safety profile similar to vaccines used in healthy adults and children. The goal of DermaVir immune intensification is to modify HIV disease, decrease drug exposure while maintaining undetectable HIV-RNA levels and achieve remission (functional cure) in HIV-infected patients.
SOURCE: Power of the Dream Ventures, Inc.
Copyright 2011 Marketwire, Inc., All rights reserved.
SUBJECT CODE: Medical and Healthcare:Health and Nutrition
Medical and Healthcare:Healthcare
Medical and Healthcare:Surgery and Treatments
Pharmaceuticals and Biotech:Trials
Pharmaceuticals and Biotech:Drugs
Pharmaceuticals and Biotech:Equipment and Supplies
Pharmaceuticals and Biotech:Biotech
To best introduce the company, please see recent article.
Elevator Pitch: Semantic web? Check. Grand ambitions? Check. iGlue? Check
Founded in August 2007 and with a staff of seven, iGlue calls itself "the superglue of the net" – and aims to be the future envy of Google.
Indexing internet pages (ring any bells?), iGlue uses technology to understand the semantic use of words and delivers related information based on text highlighted by the user.
Peter Vasko, chief executive of the three-year-old company behind iGlue In4 Kft, tells us his ambitions upon next month's launch – and reveals its closest competitor is owned by the Mountain View internet monolith Google. Peter Vasko, chief executive of the company behind iGlue, aims to have his product on every browser on the internet
• How are you funded?
"In4 Kft. [the company behind iGlue] specialises in the development of online applications based on university researches, with the participation of young university researchers. We are VC funded by Power of the Dream Ventures."
• How many users do you have now, and what's your target within
"We launch in September 2010. In 12 months we want 250,000 users."
• Explain your business to my Mum.
"Imagine you're reading an article about the recession on bbc.co.uk. Maybe you want to know more about a person or place in the article. iGlue is a little box in your internet window that lets you double click any word on any web page to learn more about it. It will give you info, maps, links, videos, images and more right there without trawling round the internet for ages."
• How does that work?
"iGlue indexes the internet but it also understands the meaning of words. So when you search 'Kennedy' it can figure out from the article if you mean politician, airport or space station. It organises info and sorts the web, therefore 'wikifying' it in the process."
• How do you make money?
"We know that search traffic is one of the most valuable commodities on the web and we believe that we can get a chunk of that. By understanding our customers more deeply we will be able to provide a discreet and effective advertising model."
• How are you surviving the downturn?
"We have received our next round of funding and we are not focusing on our public launch in September so we're happy and busy."
• What's your background?
"Web developer, researcher but also a journalist, poet and a teacher. Either way, I always look for the spot from where the view on the world is the most exciting."
• What makes your business unique?
"IGlue completely changes people's interaction with online content. We provide a huge dynamic layer of content underneath any text on the web."
• What has been your biggest achievement or proudest moment so far?
"Without a doubt Geek'n Rolla 2010, organised by TechCrunch. Not just because of the second place, but we were amazed by the buzz around us during the public demo of iGlue in the exhibition room. After the conference, even the tech and hotel staff wanted to try it!"
• Who in the tech business inspires you?
"John von Neumann, Ted Nelson, Steve Wozniak."
• What's your biggest challenge?
"Since iGlue is Hungarian and based in Budapest, it's harder for us to compete with US companies vying for the attention of VC and press who are based across the Atlantic – but we're working on it!"
• What's the most important piece of software or web tool that you use each
• Name your closest competitors.
"Apture, Open Calais, Freebase (Google), Evri."
• Where do you want the company to be in five years?
"In every web browser on the internet."
• Sell to Google, or be bigger than Google?
"Neither. Although we believe that we are building a product that will revolutionise the way people browse and experience the web. We really admire all the innovative hard work the guys at Google do. We would love to be in a position Google envies."
Power of the Dream Ventures Announces Equity Commitment of up to $5,000,000
BUDAPEST, HUNGARY, Oct 09, 2008 (MARKET WIRE via COMTEX) -- Power of the Dream Ventures, Inc. (OTCBB: PWRV), Hungary's premier technology acquisition and development company, today announced that it has finalized a financing commitment of up to $5,000,000 from a YA Global Investments, L.P. The terms of the financing allow the Company to sell up to $5,000,000 in tranches of equity, based upon a specified discount to the market price of the Company shares, calculated over the five trading days following notice of an election to sell shares.
This financing commitment provides the Company with the capital necessary to continue the development of the Company's current technology portfolio and to acquire additional technologies.
"This commitment allows us to finish executing our business plan and bring to market a number of significant technologies we have been incubating. I believe this coming year will bring significant progress for us, including the launch of our iGlue software and RiverPower technologies, among others," commented Viktor Rozsnyay, CEO of the Company. "This commitment shows trust in the company and our business model. Now it's our turn to fully execute and provide return to our investors from technology commercialization revenues," Mr. Rozsnyay added.
In connection with the financing commitment, YA Global also acquired a warrant to purchase up to an additional 4,027,386 shares of common stock.
About Power of the Dream Ventures
Power of the Dream Ventures, Inc. is a leading technology holding company. We identify and harness the unique technological prowess of Hungary's high-tech industry, turning promising ideas and ready to market products/technologies into global industry leaders. We focus on developing, acquiring, licensing, and co-developing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; emerging science and high-technology research projects that require help in patenting, developing the product and marketing, University spin-off technologies, and ideas from the very early stage that represent "disruptive technologies." We primarily focus on providing enabling solutions in the fields of environmental technologies, power generation and storage, software products and services, biotechnology, medical devices and what we call 'disruptive technologies.' For more information please visit our website at http://www.powerofthedream.com.